Insider Transactions in Q1 2021 at Collegium Pharmaceutical, Inc (COLL)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 30
2021
|
Alison B Fleming EVP & Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,984
+3.72%
|
-
|
|
Mar 16
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
734
-0.75%
|
$17,616
$24.69 P/Share
|
|
Mar 15
2021
|
Michael Thomas Heffernan Director |
SELL
Open market or private sale
|
Direct |
50,075
-64.87%
|
$1,251,875
$25.57 P/Share
|
|
Mar 01
2021
|
Joseph Ciaffoni President and CEO |
SELL
Open market or private sale
|
Direct |
64,768
-9.71%
|
$1,424,896
$22.93 P/Share
|
|
Mar 01
2021
|
Joseph Ciaffoni President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
48,616
+12.41%
|
$388,928
$8.22 P/Share
|
|
Mar 01
2021
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
6,011
-3.88%
|
$138,253
$23.36 P/Share
|
|
Feb 11
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
7,898
-4.41%
|
$197,450
$25.11 P/Share
|
|
Feb 10
2021
|
Richard Malamut EVP and Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,300
-1.17%
|
$57,500
$25.95 P/Share
|
|
Feb 10
2021
|
Paul Brannelly Executive Vice President & CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
8,491
-1.91%
|
$212,275
$25.95 P/Share
|
|
Feb 10
2021
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
23,786
-3.8%
|
$594,650
$25.95 P/Share
|
|
Feb 10
2021
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,144
-2.21%
|
$178,600
$25.95 P/Share
|
|
Feb 10
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
5,858
-2.87%
|
$146,450
$25.95 P/Share
|
|
Feb 10
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,184
-2.72%
|
$129,600
$25.95 P/Share
|
|
Jan 20
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
SELL
Open market or private sale
|
Direct |
6,081
-5.55%
|
$145,944
$24.45 P/Share
|
|
Jan 19
2021
|
Joseph Ciaffoni President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
133,989
+17.49%
|
-
|
|
Jan 19
2021
|
Paul Brannelly Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
50,161
+9.91%
|
-
|
|
Jan 19
2021
|
Shirley R. Kuhlmann EVP and General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
52,132
+18.21%
|
-
|
|
Jan 19
2021
|
Alison B Fleming EVP & Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,889
+13.14%
|
-
|
|
Jan 19
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
51,945
+19.84%
|
-
|
|
Jan 19
2021
|
Richard Malamut EVP and Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
39,147
+14.9%
|
-
|
|
Jan 15
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,322
-2.89%
|
$29,084
$22.89 P/Share
|
|
Jan 11
2021
|
Scott Dreyer EVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
701
-1.51%
|
$14,721
$21.18 P/Share
|
|
Jan 07
2021
|
Alison B Fleming EVP & Chief Technical Officer |
SELL
Open market or private sale
|
Direct |
16,042
-12.59%
|
$352,924
$22.0 P/Share
|
|
Jan 07
2021
|
Alison B Fleming EVP & Chief Technical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
16,042
+11.18%
|
$80,210
$5.73 P/Share
|
|
Jan 04
2021
|
Joseph Ciaffoni President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,090
-0.59%
|
$21,800
$20.03 P/Share
|